ICICI Prudential Healthcare Fund

(Erstwhile ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund)

(An Open Ended Equity Scheme investing in Healthcare sector)

5 YEARS COMPLETED Since 2018

Category
Sectoral

Style Box



Diversified

Returns of ICICI Prudential Healthcare Fund - Growth Option as on August 31, 2026

Particulars	1 Year		3 Years		5 Years		Since inception	
	CAGR (%)	Current Value of Investment of Rs. 10000	CAGR (%)	Current Value of Investment of Rs. 10000	CAGR (%)	Current Value of Investment of Rs. 10000	CAGR (%)	Current Value of Investment of Rs. 10000
Scheme	**10.74**	**11079.99**	**22.75**	**18504.00**	**15.30**	**20385.33**	**19.93**	**43910.00**
BSE Healthcare TRI (Benchmark)	18.70	11881.31	23.37	18788.39	14.87	20005.95	18.11	38752.82
Nifty 50 TRI (Additional Benchmark)	-0.35	9964.59	8.99	12951.19	8.32	14914.55	11.41	24089.09
NAV (Rs.) Per Unit (as on August 31,2026 : 43.91)	**39.63**		**23.73**		**21.54**		**10.00**	

Notes:
1. Different plans shall have different expense structure. The performance details provided herein are of ICICI Prudential Healthcare Fund.
2. The scheme is currently managed by Dharmesh Kakkad. Mr. Dharmesh Kakkad has been managing this fund since May 2020. Total Schemes managed by the Fund Manager(Equity) is 9 (8 are jointly managed). Refer annexure at the following link for performance of other funds being managed by the fund managers.
3. Date of inception: 13-Jul-2018.
4. Past performance may or may not be sustained in future and the same may not necessarily provide the basis for comparison with other investment.
5. Load is not considered for computation of returns.
6. In case, the start/end date of the concerned period is a nonbusiness date (NBD), the NAV of the previous date is considered for computation of returns. The NAV per unit shown in the table is as on the start date of the said period
7. The performance of the scheme is benchmarked to the Total Return variant of the Index.
8. The name of the Scheme has been changed from ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund to ICICI Prudential Healthcare Fund with effect from August 26, 2026.

Scheme Details

Fund Managers :**
Dharmesh Kakkad
(Managing this fund since May, 2020 & Overall 16 years of experience)

Indicative Investment Horizon: 5 years & above

Inception/Allotment date: 13-Jul-18

Monthly AAUM as on 31-Aug-26 : Rs. 6,873.18 crores
Closing AUM as on 31-Aug-26 : Rs. 6,995.62 crores

Application Amount for fresh Subscription :
Rs.5,000 (plus in multiple of Rs.1)

Min.Addl.Investment :
Rs.1,000 (plus in multiples of Re.1)

Exit load for Redemption / Switch out :- Lumpsum & SIP / STP Option:
1% of the applicable NAV - If units purchased or switched in from another scheme of the Fund are redeemed or switched out within 15 days from the date of allotment NIL - If units purchased or switched in from another scheme of the Fund are redeemed or switched out after 15 days from the date of allotment (w.e.f. 1st Jan 2019)

Base Expense Ratio @@ :
Other : 1.54% p. a.
Direct : 0.88% p. a.

For TER, Investor may refer to our website at https://www.icicipruamc.com/about-us/financials-&-disclosures?currentTabFilter=Total+Expense+Ratio&subCatTabFilter=Total+Expense+Ratio

NAV (As on 31-Aug-26): Growth Option : Rs. 43.91 | IDCW Option : 23.58 | Direct Plan Growth Option : Rs. 47.74 | Direct Plan IDCW Option : 26.79

Portfolio as on August 31, 2026

Company/Issuer	% to NAV
Equity Shares	**95.01%**
Chemicals & Petrochemicals	**1.22%**
Fine Organic Industries Ltd.	1.22%
Healthcare Services	**14.99%**
• Syngene International Ltd.	3.29%
Dr Agarwal's Health Care Ltd	2.79%
MAX Healthcare Institute Ltd	2.59%
Indegene Ltd.	1.92%
Metropolis Healthcare Ltd.	1.74%
Rainbow Childrens Medicare Ltd	1.36%
Thyrocare Technologies Ltd.	1.30%
Insurance	**1.13%**
Medi Assist Healthcare Services Ltd	1.13%
Pharmaceuticals & Biotechnology	**67.95%**
• Sun Pharmaceutical Industries Ltd.	12.31%
• Dr. Reddy's Laboratories Ltd.	8.26%
• Cipla Ltd.	5.76%
• Mankind Pharma Ltd.	5.21%
• Alkem Laboratories Ltd.	4.87%
• Divi's Laboratories Ltd.	4.83%
• Biocon Ltd.	4.68%
• Cohance Lifesciences Ltd.	4.08%
Alembic Pharmaceuticals Ltd.	2.48%
Abbott India Ltd.	2.38%
Akums Drugs and Pharmaceuticals Ltd.	1.99%
Astrazeneca Pharma India Ltd.	1.99%
Lupin Ltd.	1.96%
Blue Jet Healthcare Ltd.	1.93%
Pfizer Ltd.	1.86%
Alivus Life Sciences Ltd.	1.21%
Aarti Drugs Ltd.	1.10%
Hikal Ltd.	1.05%
Retailing	**5.38%**
• Medplus Health Services Ltd	4.15%
Entero Healthcare Solutions	1.23%
Equity less than 1% of corpus	**4.34%**
Short Term Debt and net current assets	**4.99%**
Total Net Assets	**100.00%**

• Top Ten Holdings
Securities and the corresponding derivative exposure with less than 1% to NAV, have been clubbed together with a consolidated limit of 10%.

Top 5 Stock Holdings

Sun Pharmaceutical Industries Ltd.	12.31%
Dr. Reddy's Laboratories Ltd.	8.26%
Cipla Ltd.	5.76%
Mankind Pharma Ltd.	5.21%
Alkem Laboratories Ltd.	4.87%

Top 5 Sector Holdings

Healthcare	87.28%
Consumer Services	5.38%
Chemicals	1.22%
Financial Services	1.13%

Quantitative Indicators

Average Dividend Yield : 1.08

Annual Portfolio Turnover Ratio : Equity - 0.74 times

Std Dev (Annualised) : 16.12%

Sharpe Ratio : 1.05

Portfolio Beta : 0.96

The figures are not netted for derivative transactions.
Risk-free rate based on the last Overnight MIBOR cut-off of 4.97%
@@ Base Expense Ratio is as on the last day of the month.
**In addition to the fund manager managing this fund, overseas investment is managed by Ms. Sharmila D'Silva.
The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P") and is licensed for use by ICICI Prudential Asset Management Company Ltd. Neither MSCI, S&P nor any other party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.
To Refer to the annexure for details on option, entry load, SWP, STP/Flex STP & minimum redemption amount pertaining to the scheme. Click here
To Refer to the annexure for details on scheme objective, IDCW history and SIP details. Click here

Riskometer

This product labelling is applicable only to the scheme

This Product is suitable for investors who are seeking*:
- Long Term Wealth Creation
- An Equity Scheme that predominantly invests in Equity and Equity related securities of companies in Healthcare Sector.

Scheme



Benchmark
(BSE Healthcare TRI)



*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.

ICICI Prudential Mutual Fund Corporate Office
ONE BKC, A - Wing, 13th Floor, Bandra-Kurla Complex, Mumbai 400 051, India.
Tel: 022 - 26525000 Fax: 022 - 26528100, website: www.icicipruamc.com, email id: enquiry@icicipruamc.com

Statutory Details & Risk Factors

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.